PMN ProMIS Neurosciences
- 1.980
- +0.030+1.54%
ProMIS Neurosciences News
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals Among Healthcare Movers
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.(NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting
Express News | ProMIS Neurosciences Q4 EPS $(0.09) Beats $(0.17) Estimate
ProMIS Neurosciences Net Loss For 2003 Narrows Vs a Year Earlier; Focus On First In-human Studies of Lead Product Candidate
ProMIS Neurosciences Inc. (Nasdaq: PMN and PMN.TO), a biotechnology company, on Monday said net loss was US$13.2 million for the full year ended December 31, 2023, compared to a net loss of $18.1 mill
ProMIS Neurosciences Reports FY Results
ProMIS Neurosciences 2023 Loss/Shr $1.07 >PMN
ProMIS Neurosciences 2023 Loss/Shr $1.07 >PMN
ProMIS Neurosciences: Top-line Data From First-In-Human Phase 1A Trial of PMN310 to Treat Alzheimer's Disease on Track for Mid-2024 >PMN
ProMIS Neurosciences: Top-line Data From First-In-Human Phase 1A Trial of PMN310 to Treat Alzheimer's Disease on Track for Mid-2024 >PMN
ProMIS Neurosciences Brief: Says Strengthened Global Intellectual Property Portfolio
07:00 AM EDT, 03/11/2024 (MT Newswires) -- ProMIS Neurosciences Brief: Says Strengthened Global Intellectual Property Portfolio
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic
Express News | ProMIS Neurosciences Has Selected The Lead Vaccine Candidate, PMN400, Against Multiple Synucleinopathies Including Multiple System Atrophy, Parkinson's Disease And Lewy Body Dementia
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic
CRGE and LAES Among Mid-day Movers
Accelerate Diagnostics, Silk Road Medical Among Healthcare Movers
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.54%
PHUN, PRQR and JSPR Among Mid-day Movers
Evolus, Leap Therapeutics Among Healthcare Movers
Analysis
Price Target
No Data
